IGMS vs. AVBP, AVTE, PHAT, CDMO, CALT, APLT, ATXS, STOK, GHRS, and OLMA
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include ArriVent BioPharma (AVBP), Aerovate Therapeutics (AVTE), Phathom Pharmaceuticals (PHAT), Avid Bioservices (CDMO), Calliditas Therapeutics AB (publ) (CALT), Applied Therapeutics (APLT), Astria Therapeutics (ATXS), Stoke Therapeutics (STOK), GH Research (GHRS), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical preparations" industry.
ArriVent BioPharma (NASDAQ:AVBP) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
IGM Biosciences received 56 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
ArriVent BioPharma presently has a consensus target price of $29.25, suggesting a potential upside of 65.25%. IGM Biosciences has a consensus target price of $17.89, suggesting a potential upside of 91.53%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe IGM Biosciences is more favorable than ArriVent BioPharma.
9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 56.9% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ArriVent BioPharma has a net margin of 0.00% compared to ArriVent BioPharma's net margin of -11,255.25%. IGM Biosciences' return on equity of 0.00% beat ArriVent BioPharma's return on equity.
ArriVent BioPharma has higher earnings, but lower revenue than IGM Biosciences.
In the previous week, IGM Biosciences had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 12 mentions for IGM Biosciences and 9 mentions for ArriVent BioPharma. IGM Biosciences' average media sentiment score of 1.27 beat ArriVent BioPharma's score of 0.39 indicating that ArriVent BioPharma is being referred to more favorably in the media.
Summary
ArriVent BioPharma beats IGM Biosciences on 7 of the 13 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
